What changed: Neuroblastoma (paediatric)
Every dated change on the records linked to Neuroblastoma (paediatric), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 4
- 2026GuidelineNeuroblastoma (paediatric)Guideline 2026: High risk: consolidation
Tandem autologous transplant (thiotepa-cyclophosphamide, then CEM) in North America (ANBL0532); single busulfan-melphalan transplant in Europe (HR-NBL1). (NCCN COG standard (tandem); SIOPEN standard (BuMel))
- 2026GuidelineNeuroblastoma (paediatric)Guideline 2026: High risk: post-consolidation
Anti-GD2 antibody (dinutuximab + GM-CSF + isotretinoin; dinutuximab beta in Europe, no IL-2) × 5-6 cycles; then eflornithine maintenance 2 years (US, 2023). (NCCN Dinutuximab: FDA-approved standard; eflornithine: FDA-approved maintenance)
- 2026GuidelineNeuroblastoma (paediatric)Guideline COG 2026: High risk: induction
5-6 cycles (COG: topotecan-cyclophosphamide × 2 then cisplatin-etoposide, cyclophosphamide-doxorubicin-vincristine; SIOPEN: rapid COJEC); stem-cell harvest; ANBL1531 adds 131I-MIBG (randomised) or lorlatinib (ALK); ANBL17P1 adds dinutuximab to induction. (NCCN COG ANBL1531 backbone)
- 2026MilestoneCOG ANBL1531ANBL1531 MIBG randomisation maturing; ALK arm reports
A milestone in how this cancer is treated.
2025 · 2
- 2025RegulatoryEflornithine (DFMO)Eflornithine (DFMO): filing accepted (EU)
MAA submitted to EMA, UK, Australia, Switzerland
- 2025MilestoneGD2-CART01 (Bambino Gesù phase 1/2)Long-term GD2 CAR-T follow-up (Nature Medicine); naxitamab primary-refractory phase 2 (75% CR); eflornithine EU filing
A milestone in how this cancer is treated.
December 2023 · 1
2023 · 5
- 2023ApprovalEflornithine (DFMO)Eflornithine (DFMO) approved in US
Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2
- 2023Trial resultGD2-CART01 (Bambino Gesù phase 1/2)GD2-CART01 (Bambino Gesù phase 1/2) reported
ORR 63%, CR 33%; 3-year OS 60%.
- 2023Trial resultNMTRC003/003B (DFMO maintenance)NMTRC003/003B (DFMO maintenance) reported
EFS HR 0.
- 2023MilestoneNeuroblastoma (paediatric)GD2 CAR-T phase 1/2 in NEJM
A milestone in how this cancer is treated.
- 2023MilestoneGD2-CART01 (Bambino Gesù phase 1/2)GD2-CART01 in NEJM: durable CAR-T remissions in a solid tumour; eflornithine approved (13 Dec)
A milestone in how this cancer is treated.
November 2020 · 1
2020 · 3
- 2020ApprovalNaxitamabNaxitamab approved in US
Relapsed/refractory high-risk neuroblastoma in bone or bone marrow with partial response, minor response or stable disease, with GM-CSF (accelerated)
- 2020Trial resultNaxitamab Study 201Naxitamab Study 201 reported
ORR 50%.
- 2020MilestoneNaxitamabNaxitamab approved for relapsed disease (accelerated)
A milestone in how this cancer is treated.
2019 · 1
May 2017 · 1
2017 · 3
- 2017ApprovalDinutuximab (ch14.18) / dinutuximab betaDinutuximab (ch14.18) / dinutuximab beta approved in EU
Dinutuximab beta: high-risk neuroblastoma after induction/transplant; relapsed/refractory disease
- 2017Trial resultSIOPEN HR-NBL1SIOPEN HR-NBL1 reported
BuMel > CEM (EFS 50% vs 38%); IL-2 adds no benefit to anti-GD2.
- 2017MilestoneSIOPEN HR-NBL1HR-NBL1: busulfan-melphalan beats CEM; IL-2 adds no benefit (2018)
A milestone in how this cancer is treated.
2016 · 2
March 2015 · 1
2015 · 2
- 2015ApprovalDinutuximab (ch14.18) / dinutuximab betaDinutuximab (ch14.18) / dinutuximab beta approved in US
High-risk neuroblastoma after at least partial response to induction, with GM-CSF, IL-2 and isotretinoin
- 2015MilestoneDinutuximab (ch14.18) / dinutuximab betaDinutuximab approved (US); dinutuximab beta in EU 2017
A milestone in how this cancer is treated.
2010 · 3
- 2010Trial resultCOG ANBL0032COG ANBL0032 reported
2-year EFS 66% vs 46%; OS 86% vs 75%.
- 2010MilestoneCOG ANBL0032ANBL0032: anti-GD2 immunotherapy raises survival ~20 points (NEJM)
A milestone in how this cancer is treated.
- 2010MilestoneNeuroblastoma (paediatric)Anti-GD2 (ch14.18) improves EFS
A milestone in how this cancer is treated.